...
首页> 外文期刊>Clinical therapeutics >Exposure– and Dose–response Analyses in Dose Selection and Labeling of FDA-approved Biologics
【24h】

Exposure– and Dose–response Analyses in Dose Selection and Labeling of FDA-approved Biologics

机译:FDA批准的生物学剂量选择和标记中的曝光和剂量 - 反应分析

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Purpose Biological drug products, or products derived from living cells, represent an increasingly important part of the pharmaceutical market. Despite this, little is known about how sponsors determine the dose to be studied in registrational trials or to be proposed in labeling for biologics. We examined how exposure–response and dose–response analyses were used to determine dosing in pivotal trials or the labeling for all biologics approved by the Center for Drug Evaluation and Research, the US Food and Drug Administration (FDA) between 2003 and 2016. Methods We extracted relevant characteristics of each biologic from its review package by FDA. We used descriptive statistics to characterize the rationale for the selected dose(s) in registration trials, with a particular focus on the role of exposure–response/dose–response analyses. We also examined how exposure–response/dose–response analyses were used to support the labeling dose and the basis for postmarketing requirements or commitments related to dose optimization. Findings A total of 79 biologics license applications were examined. Dose selection in registrational trials was more often attributed to clinical efficacy (73% of applications) than to clinical safety (42%). The dosing of products whose dose was apparently selected based on clinical efficacy was often (72%) determined by the dose–response relationship. In support of doses that were described in labeling, exposure–response analyses for efficacy were performed more commonly (53%) than dose–response analyses (21%). This trend was apparent after 2012. Implications This is the first study to summarize the justification of dose selection and the labeled dose of biologics approved by the FDA. Dose–response analyses have been often used as the rationale for dose selection of registrational studies, although exposure–response analyses are becoming more prevalent in support of the dosing guidelines in labeling.
机译:摘要目的生物药品或源自活细胞的产品,代表了药物市场的越来越重要的部分。尽管如此,对赞助商如何确定在注册试验中学习的剂量或提出的生物制剂标记。我们检查了曝光 - 反应和剂量 - 反应分析如何确定在2003年至2016年期间的药物评估和研究中心,美国食品和药物管理局(FDA)批准的所有生物学中的枢轴试验或标签中的用量。方法我们通过FDA从审查包中提取了每个生物学的相关特征。我们使用描述性统计数据来表征注册试验中所选剂量的基本原理,特别关注暴露响应/剂量 - 反应分析的作用。我们还研究了如何使用曝光响应/剂量 - 反应分析来支持标记剂量以及与剂量优化相关的邮政要求或承诺的基础。调查结果总共检查了79份生物学许可证申请。注册试验中的剂量选择更常见于临床疗效(73%的申请)而不是临床安全性(42%)。基于临床疗效的剂量显然选择的产品的剂量通常(72%)通过剂量 - 反应关系确定。为了支持标记中描述的剂量,更常见的(53%)比剂量 - 反应分析(21%)进行疗效的曝光响应分析。在2012年之后,这种趋势很明显。这是第一批总结剂量选择的理由和FDA批准的标记剂量的研究。剂量 - 反应分析通常被用作剂量选择的注册研究的基本原理,尽管曝光响应分析越来越普遍,以支持标记的给药指导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号